cevostamab (RG6160) / Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cevostamab (RG6160) / Roche
NCT05801939: Cevostamab Following CAR T Cell Therapy for RRMM

Recruiting
2
30
US
Cevostamab
University of Pennsylvania, Genentech, Inc.
Relapsed/Refractory Multiple Myeloma
05/27
05/28
PLYCOM, NCT05583617: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Recruiting
1/2
200
Europe, RoW
Cevostamab, Lenalidomide, Tocilizumab, Iberdomide, Dexamethasone
Hoffmann-La Roche
Multiple Myeloma
03/26
12/26
CAMMA 2, NCT05535244 / 2021-006816-10: A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
90
Europe, US, RoW
Cevostamab, Tocilizumab
Hoffmann-La Roche
Multiple Myeloma
02/27
02/27
CAMMA 1, NCT04910568: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
184
Europe, Canada, Japan, US, RoW
Cevostamab, Tocilizumab, Actemra/RoActemra, Pomalidomide, Daratumumab, Dexamethasone
Genentech, Inc., Hoffmann-La Roche
Multiple Myeloma
09/24
07/25
GO39775, NCT03275103: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Checkmark Data from trial for r/r multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022
Checkmark Data from trial for r/r multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: Data from trial for r/r multiple myeloma at ASH 2021
Recruiting
1
420
Europe, Canada, US, RoW
Cevostamab, BFCR4350A; RO7187797, Tocilizumab, Actemra/RoActemra
Genentech, Inc.
Multiple Myeloma
12/25
12/25
NCT05927571: A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Recruiting
1
120
RoW
Cevostamab, Elranatamab, Tocilizumab
Genentech, Inc.
Relapsed or Refractory Multiple Myeloma
07/26
07/26
NCT05646836: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1
90
Europe, RoW
Cevostamab, RO7187797, XmAb24306, RO7310729, Tocilizumab, Actemra, RoActemra
Genentech, Inc.
Multiple Myeloma
08/26
01/27

Download Options